XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net income $ 51,521 $ 13,280
Income from discontinued operations, net of tax 48,472 13,130
Income from continuing operations 3,049 150
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 13,043 11,931
Amortization 223 154
Accretion of asset retirement obligations 93 81
Bad debt expense 137 205
Stock based compensation expense, net of amount capitalized 642 2,739
Deferred income taxes 5,256 (385)
Gain from patronage and investments (432) (338)
Changes in assets and liabilities:    
Accounts receivable 1,861 2,998
Current income taxes (4,334) (388)
Operating lease right-of-use assets 669 666
Other assets (5,824) (1,732)
Accounts payable (281) 1,262
Lease liabilities (929) (416)
Other deferrals and accruals (4,037) (3,673)
Net cash provided by operating activities - continuing operations 9,136 13,254
Net cash provided by operating activities - discontinued operations 75,530 47,854
Net cash provided by operating activities 84,666 61,108
Cash flows from investing activities:    
Capital expenditures (39,482) (23,362)
Proceeds from sale of assets and other 14 263
Net cash used in investing activities - continuing operations (39,468) (23,099)
Net cash used in investing activities - discontinued operations (882) (8,926)
Net cash used in investing activities (40,350) (32,025)
Cash flows from financing activities:    
Taxes paid for equity award issuances (1,486) (1,945)
Payments for financing arrangements and other (496) (27)
Net cash used in financing activities - continuing operations (1,982) (1,972)
Net cash used in financing activities - discontinued operations (8,549) (8,530)
Net cash used in financing activities (10,531) (10,502)
Net increase in cash and cash equivalents 33,785 18,581
Cash and cash equivalents, beginning of period 195,397 101,651
Cash and cash equivalents, end of period $ 229,182 $ 120,232